Zofran
T-cell Lymphoma
Fred Hutchinson Cancer CenterPhase 2Active
B
63/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 52/ 100
- Competitive Position
- 81/ 100
Competitive context
25 Active assets in the T-cell Lymphoma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
PREDNISONE TABLETS Dizal Pharmaceuticals | Phase 3 | BB |
Inno-206 Dizal Pharmaceuticals | Phase 3 | BB |
Cyclophosphamide Dizal Pharmaceuticals | Phase 3 | BB |
DEXAMETHASONE St. Jude Children's Research Hospital | Phase 3 | BB |
(+)-VINCRISTINE St. Jude Children's Research Hospital | Phase 3 | BB |
View all 34 →
Same molecule, other indications
Zofran is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →